Most people don’t enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such ...
Australia’s audit office will probe the Morrison government’s $2 billion deal with US pharmaceutical giant Moderna to set up ...
Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...
Hosted on MSN2d
Moderna’s mRESVIA vaccine gains Health Canada approvalModerna has received Health Canada's approval for its respiratory syncytial virus messenger ribonucleic acid (mRNA) vaccine ...
Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Moderna (MRNA) announced Health Canada has approved mRESVIA for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults 60 years of ...
Both stocks have made significant breakthroughs. Among the qualities a biotech company needs to be successful, being innovative is one of the most important. It's easy to understand why. Although ...
(Reuters) -Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback